IGAN
Clinical trials for IGAN explained in plain language.
Never miss a new study
Get alerted when new IGAN trials appear
Sign up with your email to follow new studies for IGAN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New RNA drug aims to quiet overactive immune system in kidney disease
Disease control Recruiting nowThis Phase 2 study tests a drug called ADX-038 in 45 adults with kidney diseases like IgA nephropathy and C3G, which are caused by an overactive complement system (part of the immune system). The drug is an RNA molecule designed to block complement proteins. The study will check …
Matched conditions: IGAN
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 23, 2026 11:56 UTC
-
New hope for kidney disease: drug trial targets protein leak
Disease control Recruiting nowThis study tests whether the drug ravulizumab can reduce protein in the urine and protect kidney function in adults with IgA nephropathy, a disease that can lead to kidney failure. About 510 participants will receive either ravulizumab or a placebo by infusion. The goal is to see…
Matched conditions: IGAN
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 17, 2026 12:07 UTC
-
New drug shows promise for rare kidney diseases
Disease control Recruiting nowThis study tests a drug called atacicept in 200 adults and teens with several types of autoimmune kidney diseases, including IgA nephropathy and FSGS. The goal is to see if it safely reduces protein in the urine and helps protect kidney function. Participants must already be on s…
Matched conditions: IGAN
Phase: PHASE2 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:09 UTC
-
New hope for kids with kidney disease: drug trial targets protein leak
Disease control Recruiting nowThis study tests a drug called ravulizumab in children aged 2 to 18 with a kidney disease called IgA nephropathy. The goal is to see if the drug can reduce protein in the urine, a sign of kidney damage. Participants will receive the drug through an IV and be monitored for safety …
Matched conditions: IGAN
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 09, 2026 12:08 UTC